SIB-1757 je lek koji se koristi u naučnim istraživanjima. On je bio jedan od prvih jedinjenja razvijenih kao selektivni antagonisti za metabotropni glutamatni receptor podtip mGluR5.[1] On ima antihipergleziono dejstvo kod životinja.[2] SIB-1757 zajedno sa drugim mGluR5 antagonistima ima neuroprotektivne i hepatoprotektivne efekte,[3][4] i on se takođe koristi u studiranju uloge mGluR5 receptora tokom moždanog razvoja.[5]
Reference
^Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC (1999). „SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5”. The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 170—81. PMID10381773.
^Dogrul A, Ossipov MH, Lai J, Malan TP, Porreca F (2000). „Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats”. Neuroscience Letters. 292 (2): 115—8. PMID10998562. doi:10.1016/S0304-3940(00)01458-0.
^Storto M, Ngomba RT, Battaglia G, Freitas I, Griffini P, Richelmi P, Nicoletti F, Vairetti M (2003). „Selective blockade of mGlu5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice”. Journal of Hepatology. 38 (2): 179—87. PMID12547406. doi:10.1016/S0168-8278(02)00384-7.
^Fazal A, Parker F, Palmer AM, Croucher MJ (2003). „Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium-dependent re-uptake in rat cerebrocortical minislices”. Journal of Neurochemistry. 86 (6): 1346—58. PMID12950444. doi:10.1046/j.1471-4159.2003.01932.x.
^Bonsi P, Cuomo D, De Persis C, Centonze D, Bernardi G, Calabresi P, Pisani A (2005). „Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons”. Neuropharmacology. 49. Suppl 1: 104—13. PMID16005029. doi:10.1016/j.neuropharm.2005.05.012.